Now that the reporting season is over, VacZine Analytics has calculated FY2024 revenues from 10 major vaccine players* (developed markets only). We estimate these companies netted ~$55bn in revenues in 2024, an $8.8bn reduction on the FY2023 figure of $63bn. More striking is that the FY2024 figure is roughly half the amounts we previously estimated in FY2021 (~$96bn) and FY2022 (~$100bn).

Clearly much momentum, especially in COVID-19 vaccines, has been lost as global markets switched away from bulk pandemic purchasing to targeted 'at risk' endemic vaccination. The FY2024 figure is, however, +$22bn (+67%) over the pre-pandemic FY2020 figure of ~$33bn, suggesting some underlying growth in the industry.

FY2020 (pre-pandemic)
~$33bn
Baseline - developed markets, 10 players
FY2022 (peak)
~$100bn
COVID-19 vaccines ~$63bn (~62% of total)
FY2024 (latest)
~$55bn
COVID-19 vaccines ~$9bn (~14% of total)

The COVID-19 collapse

COVID-19 vaccines were worth $63bn to the industry in FY2022 (~62% of total revenues); now they are worth $9bn (FY2024, ~14% of total revenues). This figure is still sizeable compared to other mainstay vaccine segments such as pneumococcal (PCV), HPV, seasonal influenza and meningitis, but the staggering drop is affecting industry confidence. Yes, the dynamic was always inevitable, but even in the endemic phase, VacZine Analytics expected volume demand for COVID-19 vaccines to be much higher and nearing that of influenza vaccines - bearing in mind the efficacy of COVID-19 vaccines is much higher than the less-than-ideal levels seen with flu.

Aside from Janssen and AstraZeneca, who exited the business completely, Pfizer and ModernaTX have seen the largest revenue drops. Pfizer sold ~$5bn of Comirnaty vaccine (Tozinareman) in FY2024 compared with ~$37bn in FY2022 at the height of the pandemic. More recently, the product also saw a 38% drop in Q4 2024 versus the same period in 2023.1

Similarly, mRNA competitor ModernaTX saw a steep fall in SpikeVax (elasomeran containing) sales from ~$19bn FY2022 to ~$3.1bn in FY2024. ModernaTX is rightly pushing the long COVID-19 agenda for its current portfolio and has reached late stages for its next-generation mRNA-1283 product (filed) and COVID-19/influenza candidate, mRNA-1083 (filed). With COVID-19 vaccination rates at 45.0% in the >65 years age group,2 ModernaTX is hoping coverage levels may increase to influenza-like levels, which are generally higher (~70% for >65 yrs, 2023-24).3

"The sticking point is that COVID-19 waves are not always synchronous with influenza, so combination products will have a limited use window."

About ~30 million doses of COVID-19 vaccines (>18 yrs) were consumed in the 2024-2025 season (IQVIA data), far below the 147.6 million doses of influenza vaccine doses distributed (CDC figures). Unless there is a dramatic change in the epidemiology of COVID-19 calling for more uptake and/or the potential for long COVID-19 is taken more seriously, it is difficult to see why this level of demand should change.

RSV vaccines: hope, headwinds, and narrowing recommendations

Manufacturers hoped that new RSV vaccines could offset the big revenue losses in COVID-19 vaccines. The USA market saw three consecutive approvals: Pfizer's ABRYSVO in May 2023,4 GSK's AREXVY also in May 2023,5 and ModernaTX's mRNA-based mRESVIA® in May 2024.6 Despite initial uncertainties regarding underpowered RSV vaccine data in older patients (>75 yrs, frail), the early days were hopeful.

In June 2023, the two frontrunner RSV vaccines gained a lower age recommendation of >60 yrs from the US ACIP committee,6 but the shared clinical decision-making advice - described by an opinion leader at IDweek 2024 as 'wishy-washy' - no doubt hampered initial uptake. Nevertheless, in FY2023 GSK sold ~$1.5bn of AREXVY and Pfizer sold $890m of ABRYSVO, which also covers the maternal indication.

To the surprise of some, the US ACIP narrowed their first recommendations for RSV vaccine in June 2024 to target >75 yrs and persons 60-74 yrs at increased risk from RSV.7 The committee's decision, driven by new clinical data regarding Guillain Barré Syndrome (GBS) and risk-benefit balance, impacted sales growth of RSV vaccines heavily. Other committees - including the UK's JCVI8 and Germany's STIKO - also chose older age groups, e.g. 75-79 and >75 yrs respectively.

GSK
AREXVY
recombinant RSVPreF3 + AS01E
$754m
FY2024 · down from ~$1.5bn (FY2023)
Pfizer
ABRYSVO
bivalent RSVpreF
$755m
FY2024 · down from $890m (FY2023)
ModernaTX
mRESVIA®
mRNA-1345
~$25m
FY2024 · limited commercial traction

The lack of GBS safety events observed for ModernaTX's mRNA-based approach, mRESVIA®, has not resonated commercially (~$25m, FY2024) - possibly also due to questions regarding durability. We do not expect mRESVIA® to contribute much to the overall market in the near term. RSV vaccine coverage rates in the USA remain below influenza, with only 1.5%-43% of persons >75 yrs ever receiving the vaccines9 (February 2025).

VacZine Analytics view · FY2024
$3.3bn

Total RSV segment FY2024 - growing despite individual monovalent vaccine declines, with Beyfortus® (+$1.2bn) making up for AREXVY and ABRYSVO shortfalls. Still well short of early analyst forecasts of $10-12bn global sales by 2030.

Pipeline: combinations, paediatrics, and the competitive arms race

With the current US ACIP stance, the future RSV vaccine market looks hindered for the older adult/elderly group. Manufacturers are therefore looking at label expansion in younger ages (both <18 yrs and >18 yrs) at risk from RSV. Within this, the paediatric vaccine space (<5 yrs) - while we believe has good potential - still produces surprises. ModernaTX's mRNA-1345 had an FDA clinical hold in December 2024 but remains listed. GSK3389245A (ChAd155-RSV) was terminated in December 2021, but Sanofi is furthest ahead with SP0125 (toddler), which has reached Phase 3 testing.

The other dynamic is that RSV is joining other respiratory pathogens in a 'shotgun-like' R&D combination approach where manufacturers are hoping for the next differentiator. Many are investigating human metapneumovirus (hMPV) - notably AstraZeneca, Clover, Moderna, Sanofi and others - and parainfluenza virus (PIV3). While all look convincing epidemiologically, these products could bring new complications in terms of vaccination timing similar to the flu/COVID-19 combination challenge. Immune interference and a higher possibility of unexpected safety events could be issues, although Moderna's triple combination COVID-19/Flu/RSV (mRNA-1045) has reached Phase 1 testing.

When the first combination respiratory vaccine - flu/COVID-19 - hits the market, this will be a true test of whether the lay public is fatigued by so much activity in the older adult/elderly space. For any respiratory vaccine containing RSV, the overriding problem will always be narrow age-based and/or stringent committee recommendations. Indeed, these could tighten further if manufacturers price new combination vaccines at a premium. RSV monovalent vaccines in the USA private market are already among the most expensive at $295 per dose (CDC vaccines price list).

The bright spot: Beyfortus®

The good news is that RSV vaccines for older adults appear to be making a real-world impact. Preliminary data from the UK's rollout of RSV vaccine for older adults (aged 75-79) showed a 30% drop in RSV hospitalisations, despite suboptimal 40% uptake in eligible adults.10 When the equivalent USA data emerges, the vaccine-sceptic administration might be convinced these vaccines keep people out of hospital. Not many can argue against well-presented real-world evidence.

There is one unambiguous bright spot in the RSV field in terms of product revenue growth. Sanofi/AstraZeneca's Beyfortus® - although not strictly speaking an active vaccine - added $1.8bn revenues to the industry in FY2024, up from $591m in the previous year. The lost potential revenues from AREXVY and ABRYSVO were effectively made up by Beyfortus®, such that the overall RSV segment grew to $3.3bn in FY2024 (+$300m on FY2023).

Merck & Co's clesrovimab (MK-1654), once launched (PDUFA target action: June 10, 2025), will likely take some Beyfortus® revenues, but should also help grow this most promising part of the RSV segment.


References

  1. Pfizer Corporate News Release. 2024 Q4 results. February 2025. Available at: Q4-2024-Earnings-Charts-FINAL.pdf. Accessed March 2025.
  2. US Centers for Disease Control and Prevention. Vaccination Trends. Available at: cdc.gov/respiratory-viruses/data/vaccination-trends.html. Accessed March 2025.
  3. US Centers for Disease Control and Prevention. Flu Vaccination Coverage, United States, 2023-24 Influenza Season. Available at: cdc.gov/fluvaxview/coverage-by-season/2023-2024.html. Accessed March 2025.
  4. Pfizer Corporate News Release. October 22 2024. Available at: pfizer.com - ABRYSVO approval. Accessed March 2025.
  5. GSK Corporate News Release. May 2023. Available at: gsk.com - AREXVY approval. Accessed March 2025.
  6. Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023;72:793-801.
  7. US Centers for Disease Control and Prevention. MMWR. Available at: cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm. Accessed March 2025.
  8. NHS. RSV vaccine. Available at: nhs.uk/vaccinations/rsv-vaccine/. Accessed March 2025.
  9. US Centers for Disease Control and Prevention. RSV Vaccination Coverage. Available at: cdc.gov/rsvvaxview/dashboard/index.html. Accessed March 2025.
  10. Mensah AA et al. Early impact of RSV vaccination in older adults in England. The Lancet. March 24, 2025. Available at: thelancet.com.
*Companies included: GSK Biologicals, Merck & Co, Pfizer Vaccines, Sanofi Pasteur, CSL Seqirus, AstraZeneca, ModernaTX, Janssen, Novavax, Bavarian Nordic and Takeda Vaccines.